A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction
The RETREAT score retains high accuracy for predicting post-LT HCC recurrence, further supporting RETREAT-guided post-LT HCC surveillance and care.
Authors
- Sander S Florman (ORCID: https://orcid.org/0000-0002-1635-9136)
- Amit Singal (ORCID: https://orcid.org/0000-0002-2882-0436)
- Bethany Barrick
- Lauren Nephew (ORCID: https://orcid.org/0000-0003-0837-0746)
- Veeral Ajmera (ORCID: https://orcid.org/0000-0001-5626-0942)
- Parissa Tabrizian (ORCID: https://orcid.org/0000-0002-7881-7497)
- Gabriel T. Schnickel (ORCID: https://orcid.org/0000-0003-4392-2200)
- P. Jonathan Li (ORCID: https://orcid.org/0000-0002-5204-6401)
- Fanny Delebecque
- Darine Daher (ORCID: https://orcid.org/0000-0002-9977-1176)
- Shravan Dave (ORCID: https://orcid.org/0000-0002-2875-4926)
- Julio Gutiérrez (ORCID: https://orcid.org/0000-0002-2212-064X)
- Christopher Wong (ORCID: https://orcid.org/0000-0001-7907-3859)
- Felipe Gaviria (ORCID: https://orcid.org/0009-0007-0919-957X)
- John Holden (ORCID: https://orcid.org/0009-0004-0886-6746)
- Nicole E. Rich (ORCID: https://orcid.org/0000-0003-2740-8818)
- Kali Zhou (ORCID: https://orcid.org/0000-0001-8554-2906)
- Eleazar E. Montalvan-Sanchez (ORCID: https://orcid.org/0000-0002-7178-0724)
- Neil Mehta
- Francis Y. Yao (ORCID: https://orcid.org/0000-0003-0623-0715)
- Nicole Garcia (ORCID: https://orcid.org/0009-0002-8873-0616)
- Gonzalo Sapisochin
Institutions
- University of Southern California (US)
- Scripps Health (US)
- University Health Network (CA)
- University of California, San Francisco (US)
- University of Toronto (CA)
- University of California San Diego (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Hepatology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1097/hep.0000000000001297
- Citations
- 10
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 13.22
Funders
- AstraZeneca
- Cancer Prevention and Research Institute of Texas
- Gilead Sciences
- Exelixis
- Eisai
- Genentech
- University of California, San Francisco
- National Cancer Institute
- Liver Center, University of California, San Francisco